Geneva, Nov. 2 -- International Clinical Trials Registry received information related to the study (NCT07890493) titled 'Immune Checkpoint Blockade and Chemotherapy With or Without Fecal Microbiota Transplant in Advanced Non-Small Cell Lung Cancer' on Oct. 16.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Canadian Cancer Trials Group
Condition:
Non Small Cell Lung Cancer
Intervention:
Biological: LND101
Drug: Carboplatin (AUC 5 or 6)
Drug: pemetrexed
Drug: Paclitaxel
Recruitment Status: Not recruiting
Phase: Phase 2
Date of First Enrollment: December 31, 2026
Target Sample Size: 160
To know ...